How to Get Enclomiphene Citrate in Florida

What Enclomiphene Citrate Is and Why Florida Men Seek It

Enclomiphene citrate is the trans-isomer of clomiphene citrate. It acts as a selective estrogen receptor modulator (SERM) at the hypothalamus and pituitary, blocking negative estrogen feedback and raising endogenous LH and FSH output, which in turn stimulates testicular testosterone production. Because it preserves the hypothalamic-pituitary-gonadal (HPG) axis rather than suppressing it, men who want to maintain fertility or avoid testicular atrophy often prefer it over exogenous testosterone.

Kim et al. (BJU Int, 2016, N=124) found that enclomiphene citrate 12.5 mg and 25 mg daily produced statistically significant increases in serum testosterone while maintaining sperm concentrations comparable to baseline, outcomes not seen in the testosterone gel comparator arm [1]. A separate phase III study showed mean morning testosterone rising from roughly 230 ng/dL to above 400 ng/dL after 16 weeks of 25 mg daily dosing [2].

Florida's large population of men aged 30 to 60, combined with the state's mature telehealth infrastructure, has made it one of the higher-volume states for compounded enclomiphene prescriptions. The drug is not FDA-approved as a standalone product, so every prescription is filled by a 503A compounding pharmacy operating under Florida Board of Pharmacy oversight [3].

The Legal Framework for Prescribing Enclomiphene in Florida

Florida permits telehealth prescribing under Florida Statute 456.47, provided the prescriber holds an active Florida license, establishes a valid patient-provider relationship through a synchronous audio-video encounter or in-person visit, and documents a diagnosis supported by objective clinical data [4]. A text-only or asynchronous encounter alone does not satisfy the valid relationship requirement for a controlled or compounded prescription.

Enclomiphene itself is not a DEA-scheduled substance, but Florida Statute 465.0276 requires that compounded products be prescribed for an identified individual patient by a licensed practitioner [5]. That means no standing orders, no bulk dispensing, and no prescription written without a chart note showing the clinical rationale.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "We recommend confirming the diagnosis by measuring morning total testosterone on at least two separate occasions before initiating therapy." [6] Florida prescribers following that standard order labs before writing the first prescription, not after.

The HealthRX clinical team uses a three-gate framework before any enclomiphene prescription is finalized: Gate 1 confirms biochemical hypogonadism (total testosterone below 300 ng/dL on two morning samples); Gate 2 confirms the secondary or hypogonadotropic pattern (low or inappropriately normal LH and FSH); Gate 3 screens for contraindications including active liver disease, history of hormone-sensitive malignancy, or untreated hyperprolactinemia. All three gates must be cleared in the chart before the prescription is transmitted.

Exact Lab Panel Required Before a Florida Prescription

A Florida provider cannot responsibly diagnose secondary hypogonadism without objective biochemical data. Ordering the right panel upfront avoids delays and prevents a second blood draw. The core panel most Florida telehealth practices require includes:

Total testosterone (drawn between 7 a.m. and 10 a.m., two separate mornings at least 48 hours apart), LH, FSH, estradiol (sensitive LC-MS/MS assay preferred), sex hormone-binding globulin (SHBG), prolactin, PSA (men 40 and older), CBC, and a comprehensive metabolic panel [6]. Free testosterone calculated from total testosterone and SHBG adds clinical value when total testosterone sits in the borderline 300 to 400 ng/dL range [7].

Prolactin matters because a pituitary adenoma causing hyperprolactinemia will suppress LH and FSH, mimicking secondary hypogonadism; starting enclomiphene without ruling out a prolactinoma delays proper treatment and could be harmful [8]. A 2020 review in the Journal of Clinical Endocrinology and Metabolism reported that roughly 40% of men with secondary hypogonadism had an identifiable structural or functional cause that required specific management before or instead of SERM therapy [9].

Labs can be drawn at any national lab network (Quest, LabCorp) using a requisition sent electronically by your telehealth provider. Most Florida LabCorp patient service centers return testosterone results within 24 to 48 hours; the full panel including LC-MS/MS estradiol may take 72 hours [10].

Who Can Prescribe Enclomiphene Citrate in Florida

Four prescriber types hold legal authority to write this prescription in Florida:

MDs and DOs with an active Florida license prescribe without restriction. Urologists, endocrinologists, and internal medicine physicians in Florida have prescribed clomiphene-family SERMs off-label for male hypogonadism for over a decade [1].

Nurse practitioners (NPs) in Florida hold independent prescriptive authority for non-controlled substances under Florida Statute 464.012, as amended in 2023, provided they have completed their 3,000-hour supervised practice requirement [11]. Compounded enclomiphene is not a controlled substance, so an NP with full prescriptive authority may write it independently.

Physician assistants (PAs) may prescribe under a supervising physician's protocol. The supervising physician does not need to see the patient personally, but the protocol must explicitly authorize SERM prescribing for hypogonadism [12].

Telehealth providers licensed in Florida but physically located out of state may prescribe to Florida patients provided they hold an active Florida license and meet the Florida Statute 456.47 encounter standard [4]. Multi-state telehealth platforms routinely employ providers with Florida licensure for exactly this reason.

Step-by-Step Process to Get Enclomiphene in Florida

Step 1. Choose a prescriber. Select either an in-person Florida men's health clinic, a urology or endocrinology practice, or a Florida-licensed telehealth platform. Confirm the provider has experience with SERM-based testosterone optimization and will prescribe to a 503A compounding pharmacy of your choice, not only an in-house pharmacy.

Step 2. Complete the intake questionnaire. Most telehealth platforms collect a symptom history (Aging Males' Symptoms scale or similar), medication list, and self-reported morning erection frequency before the video visit. Completing this thoroughly cuts the consult time.

Step 3. Order and complete labs. The provider sends a requisition to Quest or LabCorp. Draw the sample on a weekday morning before 10 a.m. Two separate morning draws at least 48 hours apart are needed for the testosterone values [6].

Step 4. Attend a synchronous video or in-person visit. The provider reviews your lab results, medical history, and symptom burden. If both testosterone readings are below 300 ng/dL with low-normal LH and FSH, secondary hypogonadism is confirmed. The provider writes the prescription.

Step 5. Prescription transmitted to a licensed Florida 503A pharmacy. The provider sends the prescription electronically. Florida law requires 503A pharmacies to compound only upon receipt of a valid patient-specific prescription [5].

Step 6. Pharmacy compounds and ships. Most Florida 503A pharmacies ship enclomiphene citrate capsules in 12.5 mg or 25 mg strengths via USPS Priority Mail or overnight courier. Delivery from a Florida-based pharmacy to a Florida address typically takes one to three business days after compounding.

Step 7. Follow-up labs at 6 to 8 weeks. A repeat morning testosterone, LH, FSH, and estradiol confirms the dose is working. The American Urological Association's 2022 testosterone deficiency guideline recommends follow-up labs at 3 and 6 months [13].

Telehealth Providers Prescribing Enclomiphene in Florida

Florida's synchronous telehealth law allows a full clinical encounter via HIPAA-compliant video, which means men anywhere in the state, including rural areas, can access enclomiphene prescribers. Several national telehealth platforms have Florida-licensed providers who regularly diagnose and manage secondary hypogonadism with SERM therapy.

When evaluating a telehealth platform, ask: Does the provider order two separate morning testosterone draws before prescribing? Do they check LH and FSH to confirm the hypogonadotropic pattern? Will they prescribe to an independent 503A pharmacy, or only to their own affiliate? A provider who skips the two-sample confirmation or omits LH/FSH is not following Endocrine Society standards [6].

The FDA has not approved a branded enclomiphene product as of 2025. Androxal (enclomiphene citrate, Repros Therapeutics) completed phase III trials but did not receive final FDA approval [2]. Every enclomiphene prescription in the United States is therefore compounded, and every Florida telehealth provider prescribing it is doing so off-label under physician judgment, consistent with the legal framework for off-label prescribing [14].

Florida 503A Compounding Pharmacies and Enclomiphene

A 503A compounding pharmacy prepares medications for individual patients based on a valid prescription, as opposed to 503B outsourcing facilities that produce large batches without patient-specific prescriptions [3]. Florida Board of Pharmacy-licensed 503A pharmacies may legally compound enclomiphene citrate capsules when supplied with a valid Florida prescription.

Quality markers to look for in a Florida 503A pharmacy include: USP Chapter 795 compliance for non-sterile compounding, certificate of analysis (COA) from an independent third-party lab for each batch of enclomiphene active pharmaceutical ingredient (API), and documented API sourcing from an FDA-registered supplier [15]. You can verify a pharmacy's Florida license at the Florida Department of Health MQA Services Portal.

Typical pricing for compounded enclomiphene in Florida ranges from $60 to $120 per month for 25 mg daily dosing, though prices vary by pharmacy and capsule strength. Florida Medicaid does not cover enclomiphene for hypogonadism, and most commercial insurance plans classify it as not medically necessary because it lacks FDA approval for this indication [16]. Paying out-of-pocket is standard.

Transferring an Existing Enclomiphene Prescription to Florida

If you move to Florida or change pharmacies, the transfer rules depend on the prescription type. Because enclomiphene is not a controlled substance, Florida law generally permits transfer of a valid non-controlled prescription between pharmacies once [17]. In practice, most 503A pharmacies require a fresh prescription from a Florida-licensed provider rather than accepting a transfer from an out-of-state prescriber, because 503A compounding requires a patient-specific order consistent with a current patient-provider relationship.

The practical path: contact your new Florida provider, share your most recent lab results (ideally drawn within the past 3 to 6 months), and request a new prescription. If your previous provider documented your diagnosis clearly, the new Florida provider may prescribe after a single telehealth visit rather than requiring you to repeat the full two-sample lab protocol, provided the prior documentation meets Florida's valid-relationship standard [4].

Monitoring, Dose Adjustments, and Long-Term Safety in Florida Practice

Starting dose in most Florida practices is 12.5 mg to 25 mg orally once daily. Kim et al. (2016) showed that 12.5 mg produced mean testosterone increases from 227 ng/dL to 360 ng/dL at 16 weeks, while 25 mg produced increases to 412 ng/dL [1]. Dose escalation above 25 mg daily is uncommon and should be guided by repeat labs, not symptoms alone.

Estradiol monitoring matters. Enclomiphene's estrogenic agonist activity at peripheral tissues (while acting as an antagonist at the hypothalamus) can raise circulating estradiol in some men, particularly those with higher body fat [8]. A sensitive estradiol above 40 pg/mL in the context of enclomiphene use may warrant dose reduction or adjunctive management. The Endocrine Society notes that estrogenic effects of SERMs differ by tissue type, and monitoring estradiol is part of responsible SERM prescribing [6].

The longest safety data available for enclomiphene comes from the Androxal clinical program. In a 16-week randomized controlled trial (N=124), enclomiphene 25 mg daily was well tolerated; the most commonly reported adverse events were hot flushes (4.8%) and headache (3.2%), both at rates comparable to placebo [1]. Visual disturbances, a known concern with racemic clomiphene, were not reported at statistically elevated rates in enclomiphene-specific trials, though prescribers should counsel patients to report any visual changes promptly [2].

The AUA's 2022 guideline recommends measuring hematocrit at baseline and at follow-up visits [13]. Unlike exogenous testosterone, enclomiphene does not predictably raise hematocrit to polycythemia thresholds, but individual responses vary and CBC monitoring is standard.

Prior Authorization and Documentation in Florida

Florida Medicaid does not cover enclomiphene for secondary hypogonadism; coverage applies only to metformin and select agents for type 2 diabetes under the state formulary [16]. Commercial insurer prior authorization, when attempted, typically requires: (a) two documented fasting morning testosterone values below 300 ng/dL, (b) LH and FSH confirming the hypogonadotropic pattern, (c) documentation that an FDA-approved testosterone product was considered and either refused by the patient or contraindicated, and (d) the prescribing physician's attestation of off-label clinical rationale [13].

Given that most insurers deny these requests for compounded drugs, most Florida patients and providers skip the prior authorization process and pay out-of-pocket. If you want to attempt coverage, ask your provider to use ICD-10 code E23.0 (hypopituitarism) or E29.1 (testicular hypofunction) with explicit documentation linking the biochemical pattern to a hypogonadotropic mechanism.